New evidence for nicotinic acid treatment to reduce atherosclerosis

References

• Goldberger J. The etiology of Pellagra. Public Health Rep.29, 1683–1686 (1914).
   PubMedGoogle Scholar
• Bogan KL, Brenner C. Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu. Rev. Nutr.28, 115–130 (2008).
   PubMed Web of Science ®Google Scholar
• Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch. Biochem.54(2), 558–559 (1955).
   PubMed Web of Science ®Google Scholar
• Damian DL. Photoprotective effects of nicotinamide. Photochem. Photobiol. Sci.9(4), 578–585 (2010).
   PubMed Web of Science ®Google Scholar
• Knip M, Douek IF, Moore WP et al. European Nicotinamide Diabetes Intervention Trial Group. Safety of high-dose nicotinamide: a review. Diabetologia43(11), 1337–1345 (2000).
   PubMed Web of Science ®Google Scholar
• Gille A, Bodor ET, Ahmed K, Offermanns S. Nicotinic acid: pharmacological effects and mechanisms of action. Annu. Rev. Pharmacol. Toxicol.48, 79–106 (2008).
   PubMed Web of Science ®Google Scholar
• Wise A, Foord SM, Fraser NJ et al. Molecular identification of high and low affinity receptors for nicotinic acid. J. Biol. Chem.278(11), 9869–9874 (2003).
   PubMed Web of Science ®Google Scholar
• Tunaru S, Kero J, Schaub A et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med.9(3), 352–355 (2003).
   PubMed Web of Science ®Google Scholar
• Soudijn W, van Wijngaarden I, Ijzerman AP. Nicotinic acid receptor subtypes and their ligands. Med. Res. Rev.27(3), 417–433 (2007).
   PubMedGoogle Scholar
• Mrochek JE, Jolley RL, Young DS, Turner WJ. Metabolic response of humans to ingestion of nicotinic acid and nicotinamide. Clin. Chem.22(11), 1821–1827 (1976).
   PubMed Web of Science ®Google Scholar
• Pieper JA. Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety. Am. J. Health Syst. Pharm.60(13 Suppl. 2), S9–S14 (2003).
   PubMed Web of Science ®Google Scholar
• Piepho RW. The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol. Am. J. Cardiol.86(12A), 35L–40L (2000).
   Web of Science ®Google Scholar
• Iwaki M, Ogiso T, Hayashi H, Tanino T, Benet LZ. Acute dose-dependent disposition studies of nicotinic acid in rats. Drug Metab. Dispos.24(7), 773–779 (1996).
   PubMedGoogle Scholar
• Benyó Z, Gille A, Kero J et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J. Clin. Invest.115(12), 3634–3640 (2005).
   PubMed Web of Science ®Google Scholar
• Morgan JM, Capuzzi DM, Guyton JR. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am. J. Cardiol.82(12A), 29U–34U (1998).
   PubMed Web of Science ®Google Scholar
• Carlson LA. Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug. Int. J. Clin. Pract.58(7), 706–713 (2004).
   PubMed Web of Science ®Google Scholar
• McCormack PL, Keating GM. Prolonged-release nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs65(18), 2719–2740 (2005).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Betteridge J, Van Gaal L; European Consensus Panel. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr. Med. Res. Opin.21(5), 665–682 (2005).
   PubMed Web of Science ®Google Scholar
• McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch. Intern. Med.164(7), 697–705 (2004).
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol. Ther.126(3), 314–345 (2010).
   PubMed Web of Science ®Google Scholar
• Menon RM, González MA, Adams MH, Tolbert DS, Leu JH, Cefali EA. Effect of the rate of niacin administration on the plasma and urine pharmacokinetics of niacin and its metabolites. J. Clin. Pharmacol.47(6), 681–688 (2007).
   PubMed Web of Science ®Google Scholar
• Sturino CF, O’Neill G, Lachance N et al. Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524). J. Med. Chem.50(4), 794–806 (2007).
   PubMed Web of Science ®Google Scholar
• Cheng K, Wu TJ, Wu KK et al. Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans. Proc. Natl Acad. Sci. USA103(17), 6682–6687 (2006).
   PubMed Web of Science ®Google Scholar
• Lai E, De Lepeleire I, Crumley TM et al. Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1. Clin. Pharmacol. Ther.81(6), 849–857 (2007).
   PubMed Web of Science ®Google Scholar
• Paolini JF, Mitchel YB, Reyes R et al. Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am. J. Cardiol.101(5), 625–630 (2008).
   PubMed Web of Science ®Google Scholar
• Maccubbin D, Bays HE, Olsson AG et al. Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int. J. Clin. Pract.62(12), 1959–1970 (2008).
   PubMed Web of Science ®Google Scholar
• Paolini JF, Bays HE, Ballantyne CM et al. Extended-release niacin/laropiprant: reducing niacin-induced flushing to better realize the benefit of niacin in improving cardiovascular risk factors. Cardiol. Clin.26(4), 547–560 (2008).
   PubMed Web of Science ®Google Scholar
• Gleim G, Ballantyne CM, Liu N et al. Efficacy and safety profile of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemia. Br. J. Cardiol.16, 90–97 (2009).
   Google Scholar
• Clofibrate and niacin in coronary heart disease. JAMA231(4), 360–381 (1975).
   PubMed Web of Science ®Google Scholar
• Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol–niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA257(23), 3233–3240 (1987).
   PubMed Web of Science ®Google Scholar
• Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med. Scand.223(5), 405–418 (1988).
   PubMed Web of Science ®Google Scholar
• Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N. Engl. J. Med.323(19), 1289–1298 (1990).
   PubMed Web of Science ®Google Scholar
• Blankenhorn DH, Azen SP, Crawford DW et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation83(2), 438–447 (1991).
   PubMed Web of Science ®Google Scholar
• Blankenhorn DH, Selzer RH, Crawford DW et al. Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound. Circulation88(1), 20–28 (1993).
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med.345(22), 1583–1592 (2001).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation110(23), 3512–3517 (2004).
   PubMed Web of Science ®Google Scholar
• Whitney EJ, Krasuski RA, Personius BE et al. A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann. Intern. Med.142(2), 95–104 (2005).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr. Med. Res. Opin.22(11), 2243–2250 (2006).
   PubMed Web of Science ®Google Scholar
• Thoenes M, Oguchi A, Nagamia S et al. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome. Int. J. Clin. Pract.61(11), 1942–1948 (2007).
   PubMed Web of Science ®Google Scholar
• Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidaemia. J. Am. Coll. Cardiol.51(16), 1564–1572 (2008).
   PubMed Web of Science ®Google Scholar
• Lee JM, Robson MD, Yu LM et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J. Am. Coll. Cardiol.54(19), 1787–1794 (2009).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Villines TC, Stanek EJ et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med.361(22), 2113–2122 (2009).
   PubMed Web of Science ®Google Scholar
• Villines TC, Stanek EJ, Devine PJ et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis) final results and the impact of medication adherence, dose, and treatment duration. J. Am. Coll. Cardiol.55(24), 2721–2726 (2010).
   PubMed Web of Science ®Google Scholar
• Digby JE, Lee JM, Choudhury RP. Nicotinic acid and the prevention of coronary artery disease. Curr. Opin. Lipidol.20(4), 321–326 (2009).
   PubMed Web of Science ®Google Scholar
• Lamon-Fava S, Diffenderfer MR, Barrett PH et al. Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler. Thromb. Vasc. Biol.28(9), 1672–1678 (2008).
   PubMed Web of Science ®Google Scholar
• Wang W, Basinger A, Neese RA et al. Effect of nicotinic acid administration on hepatic very low density lipoprotein-triglyceride production. Am. J. Physiol. Endocrinol. Metab.280(3), E540–E547 (2001).
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Le Goff W, Guerin M, Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur. Heart J.31(2), 149–164 (2010).
   PubMed Web of Science ®Google Scholar
• Ganji SH, Kamanna VS, Kashyap ML. Niacin and cholesterol: role in cardiovascular disease (review). J. Nutr. Biochem.14(6), 298–305 (2003).
   PubMed Web of Science ®Google Scholar
• Zhang LH, Kamanna VS, Zhang MC, Kashyap ML. Niacin inhibits surface expression of ATP synthase β chain in HepG2 cells: implications for raising HDL. J. Lipid. Res.49(6), 1195–1201 (2008).
   PubMed Web of Science ®Google Scholar
• Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am. J. Cardiol.101(8A), 20B–26B (2008).
   PubMed Web of Science ®Google Scholar
• van der Hoorn JW, de Haan W, Berbée JF et al.. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice. Arterioscler. Thromb. Vasc. Biol.28(11), 2016–2022 (2008).
   PubMed Web of Science ®Google Scholar
• Guyton JR, Blazing MA, Hagar J et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch. Intern. Med.160(8), 1177–1184 (2000).
   PubMedGoogle Scholar
• Morgan JM, Capuzzi DM, Baksh RI et al. Effects of extended-release niacin on lipoprotein subclass distribution. Am. J. Cardiol.91(12), 1432–1436 (2003).
   PubMed Web of Science ®Google Scholar
• Johansson J, Carlson LA, Landou C, Hamsten A. High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler. Thromb.11(1), 174–182 (1991).
   PubMed Web of Science ®Google Scholar
• Windler E, Schöffauer M, Zyriax BC. The significance of low HDL-cholesterol levels in an ageing society at increased risk for cardiovascular disease. Diab. Vasc. Dis. Res.4(2), 136–142 (2007).
   PubMedGoogle Scholar
• Preiss D, Sattar N. Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clin. Endocrinol. (Oxf.).70(6), 815–828 (2009).
   PubMed Web of Science ®Google Scholar
• Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol.8(6), 1245–1255 (1986).
   PubMed Web of Science ®Google Scholar
• Warnholtz A, Wild P, Ostad MA et al. Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study. Atherosclerosis204(1), 216–221 (2009).
   PubMed Web of Science ®Google Scholar
• Sorrentino SA, Besler C, Rohrer L et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with Type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation121(1), 110–122 (2010).
   PubMed Web of Science ®Google Scholar
• Backes JM, Howard PA, Moriarty PM. Role of C-reactive protein in cardiovascular disease. Ann. Pharmacother.38, 110–118 (2004).
   PubMed Web of Science ®Google Scholar
• Kashyap ML, McGovern ME, Berra K et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am. J. Cardiol.89, 672–678 (2002).
   PubMed Web of Science ®Google Scholar
• Moon YS, Kashyap ML. Niacin extended-release lovastatin: combination therapy for lipid disorders. Expert Opin. Pharmacother.3, 1768–1774 (2002).
   Google Scholar
• Scheurig AC, Thorand B, Fischer B, Heier M, Koenig W. Association between the intake of vitamins and trace elements from supplements and C-reactive protein: results of the MONICA/KORA Augsburg study. Eur. J. Clin. Nutr.62(1), 127–137 (2008).
   PubMedGoogle Scholar
• Westphal S, Borucki K, Taneva E, Makarova R, Luley C. Extended-release niacin raises adiponectin and leptin. Atherosclerosis193(2), 361–365 (2007).
   PubMedGoogle Scholar
• Westphal S, Borucki K, Taneva E, Makarova R, Luley C. Adipokines and treatment with niacin. Metabolism55(10), 1283–1285 (2006).
   PubMed Web of Science ®Google Scholar
• Linke A, Sonnabend M, Fasshauer M et al. Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis205(1), 207–213 (2009).
   PubMed Web of Science ®Google Scholar
• Plaisance EP, Grandjean PW, Brunson BL, Judd RL. Increased total and high-molecular weight adiponectin after extended-release niacin. Metabolism57(3), 404–409 (2008).
   PubMedGoogle Scholar
• Knopp RH, Retzlaff BM, Fish B et al. The SLIM Study: Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia. J. Clin. Lipidol.3(3), 167–178 (2009).
   PubMed Web of Science ®Google Scholar
• Premkumar VG, Yuvaraj S, Vijayasarathy K, Gangadaran SG, Sachdanandam P. Serum cytokine levels of interleukin-1β, -6, -8, tumour necrosis factor-α and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin. Basic Clin. Pharmacol. Toxicol.100(6), 387–391 (2007).
   PubMed Web of Science ®Google Scholar
• Jin FY, Kamanna VS, Kashyap ML. Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler. Thromb. Vasc. Biol.19(4), 1051–1059 (1999).
   PubMed Web of Science ®Google Scholar
• Kamanna VS, Kashyap ML. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents? Am. J. Cardiol.100(11 A), S53–S61 (2007).
   Google Scholar
• Ganji SH, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J. Lipid. Res.45(10), 1835–1845 (2004).
   PubMed Web of Science ®Google Scholar
• Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler. Thromb. Vasc. Biol.17(10), 2020–2028 (1997).
   PubMed Web of Science ®Google Scholar
• Zhang LH, Kamanna VS, Zhang MC, Kashyap ML. Niacin inhibits surface expression of ATP synthase β chain in HepG2 cells: implications for raising HDL. J. Lipid. Res.49(6), 1195–1201 (2008).
   PubMed Web of Science ®Google Scholar
• Soga T, Kamohara M, Takasaki J et al. Molecular identification of nicotinic acid receptor. Biochem. Biophys. Res. Commun.303(1), 364–369 (2003).
   PubMed Web of Science ®Google Scholar
• Carlson LA. Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro. Acta. Med. Scand.173, 719–722 (1963).
   PubMed Web of Science ®Google Scholar
• Plaisance EP, Lukasova M, Offermanns S, Zhang Y, Cao G, Judd RL. Niacin stimulates adiponectin secretion through the GPR109A receptor. Am. J. Physiol. Endocrinol. Metab.296(3), E549–E558 (2009).
   Web of Science ®Google Scholar
• Digby JE, McNeill E, Dyar OJ, Lam V, Greaves DR, Choudhury RP. Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin. Atherosclerosis209(1), 89–95 (2010).
   PubMed Web of Science ®Google Scholar
• Maciejewski-Lenoir D, Richman JG et al. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J. Invest. Dermatol.126(12), 2637–2646 (2006).
   PubMed Web of Science ®Google Scholar
• Meyers CD, Liu P, Kamanna VS, Kashyap ML. Nicotinic acid induces secretion of prostaglandin D2 in human macrophages: an in vitro model of the niacin flush. Atherosclerosis192(2), 253–258 (2007).
   PubMed Web of Science ®Google Scholar
• Knowles HJ, te Poele RH, Workman P, Harris AL. Niacin induces PPARg expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. Biochem. Pharmacol.71(5), 646–656 (2006).
   PubMedGoogle Scholar
• Kostylina G, Simon D, Fey MF, Yousefi S, Simon HU. Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A). Cell Death Differ.15(1), 134–142 (2008).
   PubMedGoogle Scholar
• Carson DA, Seto S, Wasson DB. Pyridine nucleotide cycling and poly(ADP-ribose) synthesis in resting human lymphocytes. J. Immunol.138(6), 1904–1907 (1987).
   PubMed Web of Science ®Google Scholar
• Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat. Rev. Immunol.8(10), 802–815 (2008).
   PubMed Web of Science ®Google Scholar
• Wu BJ, Yan L, Charlton F, Witting P, Barter PJ, Rye KA. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler. Thromb. Vasc. Biol.30(5), 968–975 (2010).
   PubMed Web of Science ®Google Scholar
• Ganji SH, Qin S, Zhang L, Kamanna VS, Kashyap ML. Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis202(1), 68–75 (2009).
   PubMed Web of Science ®Google Scholar
• Tavintharan S, Lim SC, Sum CF. Effects of niacin on cell adhesion and early atherogenesis: biochemical and functional findings in endothelial cells. Basic Clin. Pharmacol. Toxicol.104(3), 206–210 (2009).
   PubMedGoogle Scholar